Evidence map›Paper›PMID 37693148›Full record

ArticleAmerican journal of cancer research2023

hsa_circ_0000519 promotes the progression of lung adenocarcinoma through the hsa-miR-1296-5p/DARS axis.

Guangxu Tu, Weilin Peng, Xiong Peng, Zhenyu Zhao, Shuai Shi, Qidong Cai, Boxue He, Wei Yin, Shaoliang Peng, Li Wang and 2 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Guangxu TuDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Weilin PengDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Xiong PengDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Zhenyu ZhaoDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Shuai ShiDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Qidong CaiDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Boxue HeDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Wei YinDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Shaoliang PengCollege of Computer Science and Electronic Engineering, Hunan University Changsha 410082, Hunan, China.
Li WangDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Fenglei YuDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Xiang WangDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University Changsha 410011, Hunan, China.
Central South University · CNHunan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging research indicates that circRNAs serve a crucial role in occurrence and development of cancers. This study aimed to uncover the biological role of hsa_circ_0000519 in the progression of LUAD (lung adenocarcinoma). hsa_circ_0000519 was identified by bioinformatic analysis, and its differential expression was validated in LUAD tissues and cell lines. CCK8, colony formation, wound healing, transwell assays, and xenograft tumor models were used to observe the biological functions of hsa_circ_0000519. FISH, RIP, dual luciferase reporter assays, and recovery experiments were implemented to explore the underlying mechanisms of hsa_circ_0000519. hsa_circ_0000519 was significantly upregulated in LUAD tissues and cell lines. The expression of hsa_circ_0000519 was positively correlated with T grade and TNM stage in patients with LUAD. Downregulation of hsa_circ_0000519 remarkably reduced cell proliferation, migration, invasion in vitro, and tumor growth in vivo. Mechanistic investigation demonstrated that hsa_circ_0000519 directly sponged hsa-miR-1296-5p to reduce its repressive impact on DARS as well as activate the PI3K/AKT/mTOR signaling pathway. The malignant phenotypes of LUAD cells induced by upregulation of hsa_circ_0000519 could be rescued by hsa-miR-1296-5p overexpression or knockdown of DARS. In conclusion, hsa_circ_0000519 promotes LUAD progression through the hsa-miR-1296-5p/DARS axis and may be expected as a novel biomarker and therapeutic for LUAD.

Indexed as

ceRNADARShsa_circ_0000519hsa-miR-1296-5pLUADPI3K/AKT/mTOR pathway

Identifiers

PMID37693148
PMCPMC10492121
OpenAlexW4386592054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.